Background
viral disease, dengue, infections, infection, Dengue
VIRAL DISEASE, DENGUE, INFECTIONS, INFECTION, DENGUE, ANTIBODY-DEPENDENT ENHANCEMENT
Dengue is the most prevalent vector-borne viral disease globally, causing between 50 and 100 million cases annually [To avoid inducing antibody-dependent enhancement, the three leading vaccine candidates - Dengvaxia, TAK-003, and TV003 – are live-attenuated, tetravalent, and aim to induce specific immunity against each serotype simultaneously. TV003 phase 1/2 trials indicate that it induces a tetravalent neutralizing antibody response in about two-thirds of subjects [Second heterotypic infection has the highest risk of severe dengue, but third and fourth infections are typically less severe [Building on previous work, we aim to evaluate how distinct DENV immunity profiles impact the viral, innate, cellular, and humoral responses to a controlled DENV exposure. Additionally, we will evaluate the paradigm of image guided serial nodal immune characterization as a key element of model design. By accounting for other variables, our study has the potential to identify novel biomarkers associated with viral replication and the process by which sequential exposure induces broadly protective dengue immunity.